SCHEMBL4428193

SCHEMBL4428193

O=C(O)c1ccc(CCc2ccccc2)[nH]c1=O

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
DAO P14920 6/20 0.54
KDM5B Q9UGL1 5/20 0.54
KDM6B O15054 4/20 0.54
KDM4A O75164 4/20 0.54
KDM4D Q6B0I6 4/20 0.54
HIF1AN Q9NWT6 4/20 0.54
KDM2A Q9Y2K7 4/20 0.54
KDM3B Q7LBC6 3/20 0.54
KDM4E B2RXH2 1/20 0.51
KDM5A P29375 1/20 0.49
GPR84 Q9NQS5 1/20 0.47
BRS3 P32247 2/20 0.46
RNASEH1 O60930 1/20 0.46
FFAR1 O14842 1/20 0.42
NAPRT Q6XQN6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3912930 0.85 KDM4E (0.53) DAOKDM5BKDM6BKDM4AKDM4D
SCHEMBL4429436 0.83 KDM4E (0.53) DAOKDM5BKDM6BKDM4AKDM4D
SCHEMBL4428237 0.82 KDM4E (0.50) DAOKDM5BKDM6BKDM4AKDM4D
SCHEMBL8326795 0.80 HTR1A (0.54) KDM5BKDM6BKDM4AKDM4DHIF1AN
SCHEMBL4430955 0.80 KDM4E (0.47) KDM5BKDM6BKDM4AKDM4DHIF1AN
SCHEMBL4432530 0.80 KDM4E (0.47) DAOKDM5BKDM6BKDM4AKDM4D
SCHEMBL4432424 0.78 HNF4A (0.49) DAOKDM5BKDM6BKDM4AKDM4D
SCHEMBL1150021 0.77 GPR84 (0.47) DAOKDM5BKDM5AGPR84BRS3
Benzylphenylether SCHEMBL8328497 0.77 NR4A2 (0.46) KDM5BKDM6BKDM4AKDM4DHIF1AN
SCHEMBL9339112 0.77 MAPT (0.49) DAOKDM5BKDM6BKDM4AKDM4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3353162-A1 PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2018-08-01 EP disclosed
EP-3344615-A1 PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) 2018-07-11 EP disclosed
WO-2017060180-A1 2-OXO-1,2-DIHYDROPYRIDINE-3,5-DICARBOXAMIDE COMPOUNDS AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-04-13 WO disclosed
WO-2017050714-A1 PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-03-30 WO disclosed
WO-2017037116-A1 PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-03-09 WO disclosed
EP-2125739-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2009-12-02 EP disclosed
WO-2008079371-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2008-07-03 WO disclosed
EP-0509769-B1 Heterocyclic amides having HLE inhibiting activity ZENECA LTD (GB) 1996-09-11 EP disclosed
US-5521179-A Heterocyclic amides ZENECA LIMITED (GB) 1996-05-28 US disclosed
EP-0509769-A2 Heterocyclic amides having HLE inhibiting activity ZENECA LIMITED (GB) 1992-10-21 EP disclosed
US-3948903-A Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins PARKE, DAVIS & COMPANY (US) 1976-04-06 US disclosed